المؤلفون: E. Kondratyeva I., E. Loshkova V., E. Nikolaeva D., M. Khachiyan M., G. Yankina N., Е. Кондратьева И., Е. Лошкова В., E. Николаева Д., М. Хачиян М., Г. Янкина Н.

المصدر: Meditsinskiy sovet = Medical Council; № 16 (2021); 166-173 ; Медицинский Совет; № 16 (2021); 166-173 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: cystic fibrosis, Pseudomonas aeruginosa, inhaled antibiotics, pulmonary exacerbations, nutritional status, vitamin D deficiency, муковисцидоз, ингаляционные антибиотики, легочные обострения, нутритивный статус, дефицит 25(ОН)D

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6475/5865Test; Кондратьева Е.И., Каширская Н.Ю., Капранов Н.И. Национальный консенсус «Муковисцидоз: определение, диагностические критерии, терапия»: проект. 2-е изд. М.: Компания БОРГЕС; 2018. 356 с. Режим доступа: https://mukoviscidoz.org/doc/konsensus/2019/konsensus-2019-bez-rentgenogramm.pdfTest.; Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS Best Practice Guidelines: the 2018 Revision. J Cyst Fibros. 2018;17(2):153–178. https://doi.org/10.1016/j.jcf.2018.02.006Test.; Zolin A., Orenti A., Naehrlich L., Jung A., van Rens J., Fox A. et al. ECFS Patient Registry. Annual Data Report. 2018 Data. Karup: European Cystic Fibrosis Society; 2020. 149 p. Available at: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdfTest.; Marshall B., Faro A., Elbert A., Fink A., Cho J., Ostrenga J. et al. Cystic Fibrosis Foundation. Patient Registry. 2019 Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 2020. 85 p. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-RegistryAnnual-Data-Report.pdfTest.; Hatziagorou E., Orenti A., Drevinek P., Kashirskaya N., Mei-Zahav M., De Boeck K. Changing Epidemiology of the Respiratory Bacteriology of Patients with Cystic Fibrosis-Data from the European Cystic Fibrosis Society Patient Registry. J Cyst Fibros. 2020;19(3):376–383. https://doi.org/10.1016/j.jcf.2019.08.006Test.; Flume P.A., Clancy J.P., Retsch-Bogart G.Z., Tullis D.E., Bresnik M., Derchak P.A. et al. Continuous Alternating Inhaled Antibiotics for Chronic Pseudomonal Infection in Cystic Fibrosis. J Cyst Fibros. 2016;15(6):809–815. https://doi.org/10.1016/j.jcf.2016.05.001Test.; Behzadi P., Baráth Z., Gajdács M. It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics (Basel). 2021;10(1):42. https://doi.org/10.3390/antibiotics10010042Test.; Шагинян И.А., Аветисян Л.Р., Чернуха М.Ю., Сиянова Е.А., Бурмистров Е.М., Воронкова А.Ю. и др. Эпидемиологическая значимость молекулярной изменчивости генома изолятов Pseudomonas aeruginosa, вызывающих хроническую инфекцию легких у больных муковисцидозом. Клиническая микробиология и антимикробная химиотерапия. 2019;21(4):340–351. https://doi.org/10.36488/cmac.2019.4.340-351Test.; Middleton P.G., Taylor-Cousar J.L. Development of Elexacaftor – Tezacaftor – Ivacaftor: Highly Effective CFTR Modulation for the Majority of People with Cystic Fibrosis. Expert Rev Respir Med. 2021;15(6):723–735. https://doi.org/10.1080/17476348.2021.1855980Test.; Paterson S.L., Barry P.J., Horsley A.R. Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis. Expert Rev Respir Med. 2020;14(1):15–30. https://doi.org/10.1080/17476348.2020.1682998Test.; Davies J.C., Martin I. New Anti-Pseudomonal Agents for Cystic Fibrosis – Still Needed in the Era of Small Molecule CFTR Modulators? Expert Opin Pharmacother. 2018;19(12):1327–1336. https://doi.org/10.1080/14656566.2018.1505864Test.; Somayaji R., Nichols D.P., Bell S.C. Cystic Fibrosis – Ten Promising Therapeutic Approaches in the Current Era of Care. Expert Opin Investig Drugs. 2020;29(10):1107–1124. https://doi.org/10.1080/13543784.2020.1805733Test.; Ciofu O., Tolker-Nielsen T. Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents – How P. aeruginosa Can Escape Antibiotics. Front Microbiol. 2019;10:913. https://doi.org/10.3389/fmicb.2019.00913Test.; Taccetti G., Francalanci M., Pizzamiglio G., Messore B., Carnovale V., Cimino G., Cipolli M. Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics (Basel). 2021;10(3):338. https://doi.org/10.3390/antibiotics10030338Test.; Козлов Р.С., Сухорукова М.В., Эйдельштейн М.В., Иванчик Н.В., Склеенова Е.Ю., Романов А.В. и др. Определение чувствительности микроорганизмов к антимикробным препаратам: клинические рекомендации. Версия 2018-3. М.: МАКМАХ; 206 с. Режим доступа: https://www.antibiotic.ru/files/321/clrec-dsma2018.pdfTest.; Шагинян И.А., Брусина Е.Б., Кондратьева Е.И., Чернуха М.Ю., Аветисян Л.Р., Амелина Е.Л. и др. Муковисцидоз (кистозный фиброз): эпидемиология и контроль хронической инфекции: клинические рекомендации (проект). М.: Министерство здравоохранения Российской Федерации; 2021. 98 с. Режим доступа: http://nasci.ru/?id=2897&download=1Test.; Poole K., Srikumar R. Multidrug Efflux in Pseudomonas Aeruginosa: Components, Mechanisms and Clinical Significance. Curr Top Med Chem. 2001;1(1):59–71. https://doi.org/10.2174/1568026013395605Test.; Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K. Comparison of Two Treatment Regimens for Eradication of Pseudomonas aeruginosa Infection in Children with Cystic Fibrosis. J Cyst Fibros. 2013;12(1):29–34. https://doi.org/10.1016/j.jcf.2012.06.001Test.; Döring G., Flume P., Heijerman H., Elborn J.S. Consensus Study Group. Treatment of Lung Infection in Patients with Cystic Fibrosis: Current and Future Strategies. J Cyst Fibros. 2012;11(6):461–479. https://doi.org/10.1016/j.jcf.2012.10.004Test.; Morton R., Doe S., Banya W., Simmonds N.J. Clinical Benefit of Continuous Nebulised Aztreonam Lysine for Inhalation (AZLI) in Adults with Cystic Fibrosis – A Retrospective Cohort Study. J Cyst Fibros. 2017:16(1):S55. https://doi.org/10.1016/s1569-1993Test(17)30340-5.; Schrumpf J.A., van der Does A.M., Hiemstra P.S. Impact of the Local Inflammatory Environment on Mucosal Vitamin D Metabolism and Signaling in Chronic Inflammatory Lung Diseases. Front Immunol. 2020;11:1433. https://doi.org/10.3389/fimmu.2020.01433Test.; Poulimeneas D., Grammatikopoulou M.G., Devetzi P., Petrocheilou A., Kaditis A.G., Papamitsou T. et al. Adherence to Dietary Recommendations, Nutrient Intake Adequacy and Diet Quality among Pediatric Cystic Fibrosis Patients: Results from the GreeCF Study. Nutrients. 2020;12(10):3126. https://doi.org/10.3390/nu12103126Test.; Кондратьева Е.И., Лошкова Е.В., Захарова И.Н., Шубина Ю.Ф., Жекайте Е.К., Никонова В.С. Оценка обеспеченности витамином D детей Москвы и Московской области. Российский вестник перинатологии и педиатрии. 2021;66(2):78–84. https://doi.org/10.21508/1027-4065-2021-66-2-78-84Test.; Larijani B., Hossein-Nezhad A., Feizabad E., Maghbooli Z., Adibi H., Ramezani M., Taheri E. Vitamin D Deficiency, Bone Turnover Markers and Causative Factors among Adolescents: A Cross-Sectional Study. J Diabetes Metab Disord. 2016;15:46. https://doi.org/10.1186/s40200-016-0266-2Test.; Zhekaite E., Kondratyeva E., Voronkova A., Sherman V., Nikonova V., Ershova E., Kostyuk S. The influence of genetic factors and phenotype on the development of vitamin D deficiency in children with Cysticic fibrosis. J Cyst Fibros. 2018;17(3):117–118. https://doi.org/10.1016/S1569-1993Test(18)30502-2.; https://www.med-sovet.pro/jour/article/view/6475Test

الإتاحة: https://doi.org/10.21518/2079-701X-2021-16-166-173Test
https://doi.org/10.1016/j.jcf.2018.02.006Test
https://doi.org/10.1016/j.jcf.2019.08.006Test
https://doi.org/10.1016/j.jcf.2016.05.001Test
https://doi.org/10.3390/antibiotics10010042Test
https://doi.org/10.36488/cmac.2019.4.340-351Test
https://doi.org/10.1080/17476348.2021.1855980Test
https://doi.org/10.1080/17476348.2020.1682998Test
https://doi.org/10.1080/13543784.2020.1805733Test
https://doi.org/10.3389/fmicb.2019.00913Test

المؤلفون: A. N. Kuzovlev, A. V. Grechko

المصدر: Общая реаниматология, Vol 13, Iss 5, Pp 69-84 (2018)

مصطلحات موضوعية: нозокомиальная пневмония, ингаляционные антибиотики, аминогликозиды, тобрамицин, колисти, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

وصف الملف: electronic resource

العلاقة: https://www.reanimatology.com/rmt/article/view/1626Test; https://doaj.org/toc/1813-9779Test; https://doaj.org/toc/2411-7110Test

الوصول الحر: https://doaj.org/article/68d1176ad8214a60a3aaf68a5e3d136aTest

المؤلفون: A. N. Kuzovlev, A. K. Shabanov, A. M. Golubev, V. V. Moroz

المصدر: Общая реаниматология, Vol 13, Iss 6, Pp 60-73 (2017)

مصطلحات موضوعية: нозокомиальная пневмония, ингаляционный колистин, ингаляционные антибиотики, небулайзер, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

وصف الملف: electronic resource

العلاقة: https://www.reanimatology.com/rmt/article/view/1619Test; https://doaj.org/toc/1813-9779Test; https://doaj.org/toc/2411-7110Test

الوصول الحر: https://doaj.org/article/c254706a984f4d4a872226513fa73544Test

المؤلفون: КУЗОВЛЕВ АРТЕМ НИКОЛАЕВИЧ, МОРОЗ В.В., ГОЛУБЕВ А.М.

مصطلحات موضوعية: НОЗОКОМИАЛЬНАЯ ПНЕВМОНИЯ, ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ, АМИНОГЛИКОЗИДЫ, ТОБРАМИЦИН

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/ingalyatsionnye-antibiotiki-v-lechenii-nozokomialnoy-pnevmoniiTest
http://cyberleninka.ru/article_covers/15897601.pngTest

مصطلحات موضوعية: ТИАМФЕНИКОЛА ГЛИЦИНАТ АЦЕТИЛЦИСТЕИНАТ, bronchiectasis, ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ, thiamphenicol glycinate acetylcysteinate, inhaled antibiotics, БРОНХОЭКТАЗЫ, ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ, chronic obstructive pulmonary disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::104731baba76a09277e9ebde2a7a97acTest

المؤلفون: S. N. Avdeev, N. А. Karchevskaya, С. Н. Авдеев, Н. А. Карчевская

المصدر: PULMONOLOGIYA; № 4 (2011); 133-138 ; Пульмонология; № 4 (2011); 133-138 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2011-0-4

مصطلحات موضوعية: тобрамицин, inhaled antibiotics, tobramycin, ингаляционные антибиотики

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/370/367Test; Reid L.M. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5: 233–247.; Barker A.F. Bronchiectasis. N. Engl. J. Med. 2002, 346: 1383–1393.; Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 1277–1284.; Cole P.J. Inflammation: a two-edged sword- the model of bronchiectais. Eur. J. Respir. Dis. 1986; Suppl. 147: 6–15.; Finklea J.D., Khan G., Thomas S. et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir. Med. 2010; 104: 816–821.; Alzeer A.H., Masood M., Jani Basha S. et al. Survival of brochiectatic patients with respiratory failure in ICU. BMC Pulm. Med. 2007; 7: 17.; Dupont M., Gacouin A., Lena H. et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125: 1815–1820.; Haworth C.S. Antibiotic treatment strategies in adults with bronchiectasis. Eur. Respir. Mon. 2011; 52, 211–222.; Vendrell M., de Gracia J., Olveira C. et al. Diagnosis and treatment of bronchiectasis. Arch. Bronconeumol. 2008; 44: 629–640.; Ho P.L., Chan K.N., Ip M.S.M. et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594–1598.; Evans S.A., Turner S.M., Bosch B.J. et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 1996; 9: 1601–1604.; Wilson C.B., Jones P.W., O'Leary C.J. et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 1997; 10: 1754–1760.; Weycker D., Edelsberg J., Oster G. et al. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12: 205–209.; Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130; 1503–1510.; Wood G.C., Boucher B.A. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20: 166–181.; Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–30.; Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.; Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.; Cheer S.M., Waugh J., Noble S. Inhaled tobramycin (TOBI): A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63: 2501–2520.; Carcas A.J., Garcia)Statue J.L., Zapater P., Frias)Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 1999; 65: 245–250.; Goldstein I., Wallet F., Nicolas)Robin A. et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 2002; 166: 1375–1381.; Makhoul I.R., Merzbach D., Lichtig C., Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: Comparison of aerosol and systemic administration. J. Infect. Dis. 1993; 168: 1296–1299.; Kahler D.A., Schowengerdt K.O., Fricker F.J. et al. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003; 23: 543–545.; Angrill J., Agusti C., de Celis R. et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–19.; Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.; Palmer L.B., Smaldone G.C., Simon S.R. et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med. 1998; 26: 31–39.; Goldstein I., Chastre J., Rouby J.J. Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents. Semin. Respir. Crit. Care Med. 2006; 27: 82–91.; Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.; Le Conte P., Potel G., Peltier P. et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 1993; 147: 1279–1282.; Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2009; 28: 253–259.; Ilowite J.S., Gorvoy J.D., Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987; 136: 1445–1449.; Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir. Care 2007; 52: 866–884.; Conrad D.J. The clinical use of aerosolized antibiotics. Clin. Pulm. Med. 2003; 10: 201–207.; Chuchalin A., Amelina E., Bianco F. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulm. Pharm. Ther. 2009; 22: 526–532.; Knowles M.R., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588–2595.; Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–485.; Couch L.A. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120 (Suppl.): 114S–117S.; Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420–1426.; Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis – AIR-BX2. http://clinicaltrials.gov/ct2/show/NCT01314716Test.; Bilton D., Bruinenberg P., Otulana B. et al. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Am. J. Respir. Crit. Care Med. 2009; 179: A3214.; O'Donnell A.E., Swarnakar R., Yahina L. et al. A placebocontrolled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur. Respir. J. 2009; 34: 231S.; https://journal.pulmonology.ru/pulm/article/view/370Test

الإتاحة: https://doi.org/10.18093/0869-0189-2011-0-4-133-138Test
https://doi.org/10.18093/0869-0189-2011-0-4Test
https://journal.pulmonology.ru/pulm/article/view/370Test

المؤلفون: Капранов, Н., Каширская, Н., Никонова, В.

مصطلحات موضوعية: МУКОВИСЦИДОЗ, ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ, P. AERUGINOSA, ТОБИ, БРАМИТОБ, КОЛИСТИН

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/opyt-ambulatornogo-primeneniya-ingalyatsionnyh-antibiotikov-u-patsientov-s-mukovistsidozom-i-sinegnoynoy-infektsieyTest
http://cyberleninka.ru/article_covers/14501207.pngTest

المؤلفون: Авдеев, Сергей, Карчевская, Н., Чучалин, А.

مصطلحات موضوعية: НОЗОКОМИАЛЬНАЯ ПНЕВМОНИЯ,ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ,ТОБРАМИЦИН

وصف الملف: text/html

الإتاحة: http://cyberleninka.ru/article/n/opyt-ispolzovaniya-ingalyatsionnogo-tobramitsina-pri-nozokomialnoy-pnevmoniiTest
http://cyberleninka.ru/article_covers/14500736.pngTest

المصدر: Анестезиология и реаниматология.

مصطلحات موضوعية: НОЗОКОМИАЛЬНАЯ ПНЕВМОНИЯ, ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ, АМИНОГЛИКОЗИДЫ, ТОБРАМИЦИН

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2806::522c2f07fc042c37b36938d1af3b9936Test
http://cyberleninka.ru/article_covers/15897601.pngTest

المصدر: Лечебное дело.

مصطلحات موضوعية: МУКОВИСЦИДОЗ, ИНГАЛЯЦИОННЫЕ АНТИБИОТИКИ, P. AERUGINOSA, ТОБИ, БРАМИТОБ, КОЛИСТИН

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2806::ab505a0d17767d773321afe20b32dd81Test
http://cyberleninka.ru/article_covers/14501207.pngTest